Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS 2503 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ISIS 2503 | EXPERIMENTAL | All patients will begin treatment at a dose of 6 mg/kg/day of ISIS 2503. ISIS 2503 at the assigned dose will be given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. No drug will be administered during the third week of each treatment cycle. |
| Name | Type | Description |
|---|---|---|
| ISIS 2503 | DRUG | Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle. |
DISEASE CHARACTERISTICS: Histologically confirmed advanced adenocarcinoma of the pancreas that is considered inoperable Measurable disease with at least 1 lesion measuring at least 2 cm in widest diameter identifiable on CT or MRI scan PATIENT CHARACTERISTICS: Age: 18 and over Performance status: E...
Top 20 of 69 competitors
ISIS 2503 was studied for the treatment of advanced pancreatic cancer. It is an investigational agent that was evaluated in a Phase 2 clinical trial in patients with advanced cancer of the pancreas. It is not an approved therapy, and no active trials of ISIS 2503 are currently listed.
ISIS 2503 was developed by Ionis Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker IONS. The company sponsored the clinical research evaluating the agent in pancreatic cancer.
ISIS 2503 is in Phase 2 development. It has been studied in a single Phase 2 trial in advanced pancreatic cancer, and that trial is now completed. No active trials of ISIS 2503 are listed, and the agent is not approved for any indication.
ISIS 2503 was evaluated in one clinical trial, NCT00005594, titled "ISIS 2503 in Treating Patients With Advanced Cancer of the Pancreas." The Phase 2 study enrolled 4 patients in the United States, was uncontrolled, and is now completed.
No. ISIS 2503 is an investigational agent and is not approved by the FDA. Its only recorded clinical study, a Phase 2 trial in advanced pancreatic cancer, has been completed, and no active trials are listed.
The Phase 2 trial of ISIS 2503 in advanced pancreatic cancer, NCT00005594, enrolled 4 patients. The study was uncontrolled, was not randomized or double blinded, and has been completed.